Blockade of tumor necrosis factor (TNF)␣ by a soluble TNF receptor fusion protein (etanercept; Enbrel) improved in vitro hemopoiesis from the marrow of patients with myelodysplastic syndrome (MDS). Therefore, we enrolled 14 MDS patients (4 RA, 2 RARS, 6 RAEB, 2 CMML), 44-80 (median 60) years old, in a pilot trial. Etanercept, 25 mg, was given twice a week s.c. for 16 weeks (increased to three times a week if no response at 8 weeks). Among 12 evaluable patients, four had rises in hemoglobin by 1-1.5 gm/dl (three) or decreased transfusion requirements (one). Two patients had increased platelet counts (54% and 73%), and two increased neutrophils (63% and 120%). Baseline TNF␣ levels, determined in all patients, did not correlate with responses. Among eight marrows available for sequential in vitro assays, four showed increases in CFU-GM of 1.5-to 5-fold at 8 weeks, whereas three showed 3-to 10-fold decrements relative to baseline. Thus, etanercept treatment resulted in moderate improvements of cytopenias in some patients, while cell counts declined in others. Additional trials are needed to evaluate its clinical efficacy in MDS.
Introduction
Myelodysplastic syndrome (MDS) frequently presents with peripheral blood cytopenia(s). Marrows, however, are generally normo-or hypercellular. Recent studies show increased rates of apoptosis and increased levels of tumor necrosis factor (TNF)␣, Fas-ligand, and other 'negative regulators' in MDS marrow. [1] [2] [3] TNF␣ and Fas-ligand induce apoptosis. Upregulation of Fas-ligand and its receptor occurs downstream of TNF␣. Blockade of TNF␣ significantly increases hemopoietic colony formation from MDS marrow in vitro. 3 Extensive use of the soluble receptor fusion protein etanercept (Enbrel) in patients with rheumatoid arthritis has shown a good safety profile and clinical benefit including increases in hemoglobin levels. 4 Thus, based on these in vitro and in vivo data, we conducted the present pilot trial in patients with MDS with peripheral blood cytopenias.
Materials and methods
This was a pilot study with planned enrollment of 14 patients with MDS by FAB criteria. 5 Patients had р20% marrow blasts, platelet counts Ͻ100 × 10 9 /l, neutrophil counts Ͻ2 × 10 9 /l or hemoglobin levels Ͻ10 g/dl (or combinations thereof). Classifications by FAB 5 System) criteria 6 are given in Table 1 . Patients could have received prior therapy other than hemopoietic stem cell transplantation but could not receive concurrent therapy with hemopoietic growth factors.
Evaluation included physical examination, blood cell counts, serum chemistry survey, marrow aspirates for morphologic, flow cytometric and cytogenetic analysis, and in vitro studies of hemopoiesis and TNF␣ determination in marrow plasma as described. 3 Patients received etanercept (Enbrel, Immunex, Seattle, WA, USA), 25 mg s.c. twice a week; at 8 weeks, all studies were repeated. If no hematologic improvement was observed, etanercept was to be increased to three injections per week, and at 16 weeks, patients were reevaluated and all studies were again repeated.
Evaluations were carried out at the Fred Hutchinson Cancer Research Center or at Stanford University Medical Center. Etanercept was self-administered by the patients. All patients had given informed consent according to the procedures in place at the participating institutions.
Response criteria
The objective was to determine the biologic activity of etanercept in MDS. The protocol defined responses as follows: with absolute neutrophil counts (ANC) of р0.25 × 10 9 /l or platelet counts of р10 × 10 9 /l, increases to у0.5 × 10 9 /l and у20 × 10 9 /l, respectively; with ANC Ͼ0.25 × 10 9 /l or platelets Ͼ10 × 10 9 /l, a doubling of counts. For hemoglobin, increases by у1 g/dl or decreases in transfusion requirements were considered responses. Duration of improvement was monitored but was not a criterion for response. The recently published response criteria 7 were not available at initiation of this trial, and the study was, therefore, designed and evaluated without consideration of those criteria.
Results and discussion
Of 14 patients enrolled in the trial, two had etanercept discontinued because of infection. Among 12 evaluable patients, three had rises in hemoglobin of 1-1.5 g/dl by 5-6 weeks of therapy, and one required fewer RBC transfusions (from every 4 to every 7 weeks; requirements increased again upon stopping etanercept) ( Table 1) . Two patients also showed increases in platelet counts (37 to 72, and 100 to 154 × 10 9 /l, respectively), and two had increases in neutrophils from 1.6 to 3.3 and from 1.6 to 2.6 × 10 9 /l, respectively, although increments did not meet predefined response criteria in all instances. Two additional patients showed rises in ANC above already normal baseline levels possibly related to disease evolution. In some patients, peripheral blood cell counts declined during therapy. All but one response occurred during the first 8 weeks of therapy. The starting dose of etanercept of 25 mg s.c. twice a week was based on extensive investigations in patients with rheumatoid arthritis, in whom higher doses were unlikely to increase response rates. 4 The limited data of the present study suggest a similar dose-response pattern in patients with MDS.
In one patient (RAEB, 7% marrow blasts), blasts increased to 25% over 8 weeks. No substantial marrow changes occurred in the remaining patients. Flow cytometric analysis (using 18 CD specificities) and cytogenetics of marrow cells remained unchanged after therapy in all patients.
Pre-treatment TNF␣ levels in marrow plasma were elevated in all patients studied (8.3 to 28 (median 12) pg/ml vs 4.3-9.1 (median 5.7) ng/ml in 10 normal volunteers; P = 0.02). However, baseline levels and treatment responses did not correlate. Post-treatment TNF␣ levels were not interpretable since free and etanercept-bound TNF␣ could not be distinguished. Other investigators showed that treatment of MDS with ciprofloxacin and pentoxifylline ± dexamethasone to reduce TNF␣ production resulted in hematologic responses, which were more likely with high TNF␣ levels. 8 However, while treatment in that study was associated with decreases in TNF␣ levels, decreases were observed in both responders and nonresponders. 8 Among eight patients in the present study with marrow aspirates available before and after 8 weeks of therapy, four (three of whom had in vivo improvements) showed post-treatment increases in CFU-GM from baseline values of 33-187 colonies/5 × 10 5 cells to 47-502 colonies/5 × 10 5 cells, whereas three (all without in vivo improvement) showed decreases in CFU-GM from 75-138 to 7-112 colonies/5 × 10 5 cells. In one patient, colony numbers remained unchanged. Overall, etanercept was well tolerated. However, four patients developed infections: two, sore throats, one, a calf Leukemia cellulitis, and one, pneumonia requiring antibiotic therapy. All four patients were neutropenic. The latter two (patients 13 and 14) required short-term hospitalization for i.v. antibiotics, were given G-CSF, had etanercept discontinued, and were not evaluable for responses.
In summary, this pilot study suggests that etanercept has biologic activity in MDS. However, the limited responses in patients whose blood cell counts improved (and the worsening of blood cell counts in other patients) are consistent with the notion that TNF␣ accounts for only part of the observed dysregulation of hemopoiesis in MDS. This is in agreement with the emerging picture of complex interactions of multiple regulatory factors in MDS marrow. For example, we 3 and others 9 observed that Fas-associated phosphatase-1 (FAP-1), which counteracts Fas-mediated apoptosis, is downregulated in patients with MDS, 3 and the data suggest that downregulation is mediated by TNF␣. 1, 9 Functional studies using marrow CFU-GMs as a parameter yielded varying results, likely reflecting the heterogeneity of both MDS hemopoietic precursors and the patient population under study. Given these findings, use of etanercept in combination with other agents in an attempt to improve hemopoiesis should be investigated. Future studies will also need to incorporate response criteria, that are now being established, in their proposed 7 or modified form.
